Homology Medicines Inc (NASDAQ:FIXX) was the target of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 3,510,000 shares, a growth of 15.1% from the January 15th total of 3,050,000 shares. Currently, 11.6% of the company’s shares are short sold. Based on an average daily trading volume, of 352,500 shares, the short-interest ratio is presently 10.0 days.

Several brokerages have recently commented on FIXX. Oppenheimer initiated coverage on Homology Medicines in a research note on Friday, November 1st. They issued a “market perform” rating on the stock. Zacks Investment Research raised Homology Medicines from a “sell” rating to a “hold” rating in a research report on Saturday, January 4th. BidaskClub upgraded shares of Homology Medicines from a “sell” rating to a “hold” rating in a report on Friday, February 7th. HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of Homology Medicines in a report on Thursday, February 6th. Finally, FIX started coverage on shares of Homology Medicines in a research report on Thursday, October 31st. They issued a “market perform” rating on the stock. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Homology Medicines has an average rating of “Buy” and an average target price of $31.40.

Homology Medicines stock traded up $0.36 during trading on Friday, hitting $18.84. The company had a trading volume of 129,600 shares, compared to its average volume of 273,935. The stock has a market cap of $811.12 million, a price-to-earnings ratio of -7.75 and a beta of 0.39. Homology Medicines has a 1-year low of $11.05 and a 1-year high of $31.80. The company’s 50 day simple moving average is $17.82 and its 200-day simple moving average is $17.13.

Homology Medicines (NASDAQ:FIXX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.09). Homology Medicines had a negative return on equity of 43.33% and a negative net margin of 4,740.81%. The firm had revenue of $0.44 million for the quarter, compared to analyst estimates of $0.38 million. On average, equities analysts anticipate that Homology Medicines will post -2.61 earnings per share for the current year.

In other Homology Medicines news, CFO W Bradford Smith sold 6,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $16.21, for a total transaction of $97,260.00. Following the completion of the sale, the chief financial officer now owns 6,000 shares of the company’s stock, valued at $97,260. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Albert Seymour sold 9,300 shares of the firm’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $16.06, for a total value of $149,358.00. Following the sale, the insider now directly owns 172,450 shares of the company’s stock, valued at approximately $2,769,547. The disclosure for this sale can be found here. Insiders have sold a total of 809,306 shares of company stock valued at $13,748,904 in the last 90 days. Insiders own 33.40% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. UBS Asset Management Americas Inc. purchased a new stake in Homology Medicines during the fourth quarter worth about $226,000. Bank of New York Mellon Corp grew its position in Homology Medicines by 3.6% during the fourth quarter. Bank of New York Mellon Corp now owns 93,254 shares of the company’s stock worth $1,931,000 after buying an additional 3,243 shares during the period. Goldman Sachs Group Inc. grew its position in Homology Medicines by 35.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 51,007 shares of the company’s stock worth $1,055,000 after buying an additional 13,443 shares during the period. Virtus ETF Advisers LLC purchased a new position in Homology Medicines in the fourth quarter valued at about $412,000. Finally, Amia Capital LLP purchased a new position in Homology Medicines in the fourth quarter valued at about $426,000. Institutional investors and hedge funds own 73.80% of the company’s stock.

Homology Medicines Company Profile

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Further Reading: Dividend Achievers

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.